The missing link between clinical endpoints and drug targets in depression

Area of Science:

• Neuroscience and Psychiatry
• Pharmacology and Drug Development

Background:

• Mood disorders, particularly depression, are targeted by novel neurochemical interventions.
• Drug screening aims to identify clinically differentiated antidepressant agents.
• Global disease severity measures, such as the Hamilton Depression Rating Scale (HAM-D), are standard endpoints for assessing treatment response.

Purpose of the Study:

• To discuss the limitations of global scales and their individual items in discriminating antidepressant treatment response.
• To highlight the insensitivity of current measures to the mechanisms of action of existing antidepressant drugs.
• To argue for the unlikelihood of differentiating novel compounds using summary clinical scales.

Main Methods:

• Review and critical analysis of existing evidence on the sensitivity of global depression scales.
• Examination of the utility of individual Hamilton Depression Rating Scale (HAM-D) items in clinical trials.
• Discussion of the implications for drug screening and the development of novel antidepressant compounds.

Main Results:

• Individual items of the Hamilton Depression Rating Scale (HAM-D) demonstrate insensitivity to the mechanisms of action of current antidepressants.
• Limited ability to distinguish between active treatment and placebo effects using conventional global scales.
• Anticipated difficulty in differentiating novel antidepressant compounds based solely on summary clinical scale outcomes.

Conclusions:

• Summary clinical scales are unlikely to effectively differentiate novel antidepressant compounds.
• A mechanism-based approach is necessary to address the multidimensional nature of depression symptoms.
• Development of composite endpoints reflecting underlying mechanisms of action is urgently required for accurate assessment.